3-氨基-4-甲氧基苯甲胺双盐酸盐 | 60518-02-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-氨基-4-甲氧基苯甲胺双盐酸盐
• 英文名称: 3-amino-4-methoxybenzylamine
• 英文别名: 5-(aminomethyl)-2-methoxyaniline
• CAS: 60518-02-7
• 化学式: C₈H₁₂N₂O
• 分子量: 152.196
• InChiKey: PPJILWNZWLDSCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  61.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  3-氨基-4-甲氧基苯甲胺双盐酸盐 在 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium carbonate 、 三乙胺 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 四氢呋喃 、 叔丁醇 为溶剂， 反应 22.0h， 生成 benzyl (4-methoxy-3-((4-((2-(methylcarbamoyl)phenyl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)benzyl)carbamate
  参考文献：
  名称：

  选择性，共价G蛋白偶联的受体激酶5抑制剂的基于结构的设计。

  摘要：

  G蛋白偶联受体（GPCR）激酶（GRKs）调节GPCR脱敏的能力使GRK2和GRK5成为治疗心力衰竭和其他疾病（例如癌症）的有吸引力的靶标。尽管在开发对GRK2具有选择性的抑制剂方面取得了进展，但有关GRK5选择性化合物的报道却很少。在本文中，我们描述了与该亚家族独特的非保守半胱氨酸（Cys474）共价相互作用的GRK5亚家族选择性抑制剂5和16d的开发。化合物5和16d具有高度适应性的吡咯并嘧啶支架，可提供高纳摩尔至低微摩尔活性，可通过具有各种反应性和几何结构的Michael受体轻松对其进行修饰。

  DOI：

  10.1021/acsmedchemlett.9b00365
• 作为产物：
  描述：

  N-[(4-甲氧基苯基)甲基]乙酰胺 在 盐酸 、 tin 、 硝酸 作用下， 生成 3-氨基-4-甲氧基苯甲胺双盐酸盐
  参考文献：
  名称：

  Goldschmidt; Polonowska, Chemische Berichte, 1887, vol. 20, p. 2407

  摘要：

  DOI：

文献信息

• [EN] 3H-IMIDAZO [4, 5 -C] PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS<br/>[FR] 3H-IMIDAZO[4,5-C]PYRIDINE-6-CARBOXAMIDES EN TANT QU'ANTI-INFLAMMATOIRES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010100249A1

  公开（公告）日：2010-09-10

  The present invention relates to compounds of general formula (I) in which A, L, M, Q2, Q3, Q4, R1, R5, Ra, Rb, Rc, W, X, Y, Z1, Z2, Z3 are defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof. The compounds are of potential utility in the treatment and/or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and/or prevention of pain. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.

  本发明涉及通式(I)中的化合物，其中A、L、M、Q2、Q3、Q4、R1、R5、Ra、Rb、Rc、W、X、Y、Z1、Z2、Z3在描述中有定义，及其盐，特别是其生理上可接受的盐。这些化合物可能在治疗和/或预防炎症性疾病及相关症状方面具有潜在的用途，特别是在治疗和/或预防疼痛方面。本发明还涉及将这些化合物用作药物、含有它们的药物组合物以及它们的制备。
• NEW COMPOUNDS
  申请人：PFAU Roland

  公开号：US20120196897A1

  公开（公告）日：2012-08-02

  The present invention relates to compounds of general formula I in which A, L, M, Q 2 , Q 3 , Q 4 , R 1 , R 5 , R a , R b , R c , W, X, Y, Z 1 , Z 2 , Z 3 are defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof. The compounds are of potential utility in the treatment and/or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and/or prevention of pain. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.

  本发明涉及一般式I的化合物，其中A，L，M，Q2，Q3，Q4，R1，R5，Ra，Rb，Rc，W，X，Y，Z1，Z2，Z3在描述中定义，其盐，特别是其生理上可接受的盐。这些化合物在治疗和/或预防炎症性疾病和相关病症方面具有潜在的用途，特别是在治疗和/或预防疼痛方面。本发明还涉及将这些化合物用作药物、包含它们的制药组合物以及它们的制备。
• Pyridazinone derivatives useful as glucan synthase inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2586778A2

  公开（公告）日：2013-05-01

  In its many embodiments, the present invention provides -substituted pyridazinone compounds as glucan synthase inhibitors, methods of preparing such compounds, pharmaceutical including one or more of such compounds, methods of preparing pharmaceutical formulations including one or more such compounds or one or more such compounds along with other antifungal agents, and methods of treatment, prevention, inhibition, or amelioration of one or more fungal infections associated with glucan synthase using such compounds or pharmaceutical compositions.

  在其许多实施方案中，本发明提供了作为葡聚糖合成酶抑制剂的-取代哒嗪酮化合物、制备此类化合物的方法、包括一种或多种此类化合物的药物、制备包括一种或多种此类化合物或一种或多种此类化合物与其他抗真菌剂的药物制剂的方法，以及使用此类化合物或药物组合物治疗、预防、抑制或改善与葡聚糖合成酶相关的一种或多种真菌感染的方法。
• Synthesis of potent and selective 2-azepanone inhibitors of human tryptase
  作者：Guohua Zhao、Scott A. Bolton、Chet Kwon、Karen S. Hartl、Steven M. Seiler、William A. Slusarchyk、James C. Sutton、Gregory S. Bisacchi

  DOI：10.1016/j.bmcl.2003.11.016

  日期：2004.1

  The serine protease tryptase has been associated with a broad range of allergic and inflammatory diseases and, in particular, has been implicated as a critical mediator of asthma. The inhibition of tryptase therefore has the potential to be a valuable therapy for asthma. The synthesis, employing solution phase parallel methods, and SAR of a series of novel 2-azepanone tryptase inhibitors are presented. A member of this series, 8t, was identified as a potent inhibitor of human tryptase (IC50 = 38 nM) with selectivity less than or equal to330-fold versus related serine proteases (trypsin, plasmin, uPA, tPA, APC, alpha-thrombin, and FXa). (C) 2003 Elsevier Ltd. All rights reserved.
• 3H-IMIDAZO [4, 5 -C]PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2403852A1

  公开（公告）日：2012-01-11